Several major physio-pathological processes, including cancer, inflammatory states and thrombosis, are all strongly dependent upon the fine regulation of proteolytic enzyme activities, and dramatic are the consequences of unbalanced equilibria between enzymes and their cognate inhibitors. In this perspective, the discovery of small-molecule ligands able to modulate catalytic activities has a massive therapeutic potential and is a stimulating goal. Numerous recent experimental evidences revealed that proteolytic enzymes can be opportunely targeted, reporting on small ligands capable of binding to these biological macromolecules with drug-like potencies, and primarily with comparable (or even higher) efficiency with respect to their endogenous binding partner. In particular, natural occurring polyphenols and their derivatives recently disclosed these intriguing abilities, making them promising templates for drug design and development. In this review, we compared the inhibitory capacities of a set of monomeric polyphenols toward serine proteases activity, and finally summarized the data with an emphasis on the derivation of a pharmacophore model. © 2009 John Wiley and Sons A/S.
Natural occurring polyphenols as template for drug design. Focus on serine proteases / Cuccioloni, M.; Mozzicafreddo, M.; Bonfili, L.; Cecarini, V.; Eleuteri, A. M.; Angeletti, M.. - In: CHEMICAL BIOLOGY & DRUG DESIGN. - ISSN 1747-0277. - 74:1(2009), pp. 1-15. [10.1111/j.1747-0285.2009.00836.x]